J.T. Thigpen

Nova Southeastern University — United States

Medicine · Health Sciences

44h-index12.6kcitations266works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Ovarian cancer diagnosis and treatment(142), Endometrial and Cervical Cancer Treatments(111), Intraperitoneal and Appendiceal Malignancies(42), Cervical Cancer and HPV Research(37), Cancer Treatment and Pharmacology(19)

Publications265 total

Influence of Extended-Release Tacrolimus Metabolism Rate on BKV Infection in Renal Transplant Recipients
American Journal of Transplantation·2025
EPH19 Opioid-Related Overdose Death Rates in the US From 2005 to 2021
Value in Health·2024Open Access
Francis S. Morrison MD—Tribute to an apheresis leader
Journal of Clinical Apheresis·2023Open Access
EPH16 Opioid-Related Overdose Deaths in the South Region of the U.S. from 2013 to 2020
Value in Health·2023Open Access
Does P3 OSCE Performances Accurately Predict APPE Readiness
Digital Commons - East Tennessee State University (East Tennessee State University)·2020
Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240)
eScholarship (California Digital Library)·2017Open Access
Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240)
The Lancet·2017· 658 citedOpen Access
Factors Associated With Deciding Between Risk-Reducing Salpingo-oophorectomy and Ovarian Cancer Screening Among High-Risk Women Enrolled in GOG-0199: An NRG Oncology/Gynecologic Oncology Group Study
Obstetrical & Gynecological Survey·2017· 1 cited
A stratified randomized double-blind phase II trial of celecoxib for treating patients with cervical intraepithelial neoplasia: The potential predictive value of VEGF serum levels: An NRG Oncology/Gynecologic Oncology Group study
Gynecologic Oncology·2017· 20 citedOpen Access
Factors associated with deciding between risk-reducing salpingo-oophorectomy and ovarian cancer screening among high-risk women enrolled in GOG-0199: An NRG Oncology/Gynecologic Oncology Group study
Gynecologic Oncology·2017· 25 citedOpen Access
Is age a prognostic biomarker for survival among women with locally advanced cervical cancer treated with chemoradiation? An NRG Oncology/Gynecologic Oncology Group ancillary data analysis
eScholarship (California Digital Library)·2016Open Access
Is age a prognostic biomarker for survival among women with locally advanced cervical cancer treated with chemoradiation? An NRG Oncology/Gynecologic Oncology Group ancillary data analysis
Gynecologic Oncology·2016· 49 citedOpen Access
A phase II study of paclitaxel for the treatment of ovarian stromal tumors: An NRG Oncology/ Gynecologic Oncology Group Study
Gynecologic Oncology·2015· 32 citedOpen Access
Adjuvant Chemotherapy in High-Risk Endometrial Carcinoma1
2015
Chemotherapy in Advanced or Recurrent Endometrial Carcinoma1
2015
Contemporary phase III clinical trial endpoints in advanced ovarian cancer: assessing the pros and cons of objective response rate, progression-free survival, and overall survival
Gynecologic Oncology·2014· 14 cited
Ovarian cancer clinical trial endpoints: Society of Gynecologic Oncology white paper
Gynecologic Oncology·2013· 69 citedOpen Access
Response as a Measure of Treatment Efficacy in Clinical Trials: Should RECIST Be Abandoned?
2013
Self-Testing Improves Student Scores on Subsequent Exams
Digital Commons - East Tennessee State University (East Tennessee State University)·2013
Cytokine use and survival in the first-line treatment of ovarian cancer: A Gynecologic Oncology Group Study
Gynecologic Oncology·2012· 9 cited
page 1 of 14Next →

Frequent Co-authors

John A. Blessing(9), Howard D. Homesley(7), Philip J. DiSaia(5), William T. Creasman(5), Peter G. Rose(4), Brian N. Bundy(4), Marcus E. Randall(4), Mark F. Brady(4), Gini F. Fleming(4), D. Scott McMeekin(4), Charles F. Streckfus(4), Lenora Bigler(4), Holly H. Gallion(4), Michael W. Sill(3), Bradley J. Monk(3), Ralph Vance(3), Chunqiao Tian(3), E. Blake Watkins(2), Daniel L. Clarke‐Pearson(2), Virginia L. Filiaci(2)